Linda E. Carlson, PhD, Discusses Importance of Reliability, Validity in Patient-Reported Outcomes of Pain

Video

An industry leader in psychosocial oncology detailed the importance of patient-reported outcomes to the field as a whole and emphasized a number of key details to remember when examining these end points.

Linda Carlson, PhD, from the Cumming School of Medicine at the University of Calgary, discussed the emergence of patient-reported outcomes (PROs) in the field of oncology, responding to a review article that was published in the journal ONCOLOGY®.

The article, entitled “Patient-Reported Outcomes of Pain and Related Symptoms in Integrative Oncology Practice and Clinical Research: Evidence and Recommendations,” summarized current and validated PROs in regard to cancer-related pain.

The authors, including Iris Zhi, MD, PhD, and Ting Bao, MD, DABMA, MS, of the Memorial Sloan Kettering Cancer Center, and Xin Shelley Wang, MD, MPH, of The University of Texas MD Anderson Cancer Center, spoke about their research on a recent episode of CancerNetwork's podcast, “Oncology Peer Review On-The-Go.”

Carlson focused her attention on the review article, specifically on the importance of reliability and validity of PROs as well as their emergence into mainstream oncology.

“First of all, I’m just happy to see that mainstream oncology is embracing this field of patient-reported outcomes and really listening to the patient experience, especially when we’re talking about something like pain, which is a personal experience,” explained Carlson. “There’s no scan you can do or measure pain without talking to the person about their experience. It’s innately an internal experience that there’s no other way to get at.”

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content